EYPT

Announcements

Nothing here yet

Daily updates

• EyePoint Pharmaceuticals reported a second Phase 3 failure for DURAVYU in wet age-related macular degeneration, after the drug failed to meet non-inferiority endpoints versus Eylea.Oct 19, 2026
• DURAVYU Phase 3 trial missed its primary endpoint in wet AMDAug 17, 2026

FDA designations

Nothing here yet

News

• EyePoint reports topline results from LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet age-related macular degenerationOct 19, 2026
• EyePoint announced topline results from LUGANO, the first of two pivotal Phase 3 trials of DURAVYU 2.7 mg in wet AMDAug 17, 2026
• EyePoint completed enrollment in both pivotal Phase 3 trials of DURAVYU for diabetic macular edemaJul 31, 2026
• EyePoint dosed the first patients in both global Phase 3 trials of DURAVYU™ for diabetic macular edemaMar 2, 2026
• EyePoint announced positive recommendation from independent data safety monitoring committee for pivotal Phase 3 trials for DURAVYU™ in wet age-related macular degenerationNov 19, 2025